Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

PRE-CLOSE TRADING STATEMENT

22 Jan 2015 07:00

RNS Number : 8047C
Cello Group plc
22 January 2015
 

FOR IMMEDIATE RELEASE 

22 JANUARY 2015

Cello Group plc

('Cello' or the 'Group')

PRE-CLOSE TRADING STATEMENT

Cello, the health and consumer strategic marketing group, today publishes the following trading update for the year ended 31 December 2014.

The Group has experienced strong trading for the year, with revenues and headline profits in line with consensus market expectations.

Highlights

- Cello Health maintains strong headline revenue growth and 20% operating margins

- Recent investments in iS Healthcare Dynamics and Promedica already bedding in well

- Recent investments in overseas expansion performing to plan

- Good momentum into 2015 from strong bookings in Q4 2014

Cello Health

Cello Health delivered double digit revenue growth, whilst maintaining 20% operating margins. The majority of Cello Health's revenues come from outside the UK, with the US being the primary overseas growth market. The acquisition of iS Healthcare Dynamics in May 2014 has proved a rapid success, reinforcing the global medical communications capability the Group can offer clients. The acquisition of Promedica in December 2014 has given Cello Health a presence on the West Coast of the USA enabling access to existing clients and the large biotech community there.

The integrated proposition and capabilities of Cello Health have resulted in the winning of a number of high profile contracts which the Group would not otherwise have secured. As a consequence, the last quarter of 2014 secured a strong new business pipeline for 2015, providing confidence for the new year. Of particular note is a multi capability contract secured from a major pharmaceutical client which is worth at least $7m a year.

Cello Signal

Full year revenue growth in Cello Signal was achieved across the year, against a tough comparator for the second half of 2013 which was influenced heavily by a one off project at the time.

The rapid transition to a digital product suite included continued investment in Pulsar, which generated an approximately £0.4m headline operating loss for the period on £1.2m of revenues. These revenues continue to grow. The acquisition of Line Digital in May 2014 has bedded in well and been fully integrated with Blonde, Signal's core technology business.

The overseas presence of Signal has been enhanced with new offices in New York, Singapore and Hong Kong, increasing the ability to service global contracts, although reducing operating margins in the short term.

Several large multi-year contracts were secured against global technology competitors, which have confirmed the validity of the growth strategy for Signal.

A restructuring charge of £0.5m has been incurred in the process of continuing the transition of Signal to delivering global technology solutions.

Bookings momentum towards the end of 2014 provides Signal with a solid platform for 2015.

Balance Sheet

Overall cash flow was delivered as planned, accounting for acquisition costs, increases and acceleration of dividend and the anticipated working capital outflow. Net debt at 31 December 2014 was approximately £7.0m, which remains well below 1 times EBITDA.

In 2014 the Group secured an extension of the existing facility with RBS until April 2018, at reduced cost.

VAT issue

Following discussion between HMRC, The Direct Marketing Association and The Charity Tax Group regarding the VAT status of the supply of certain goods and services to charities, one of Cello Signal's subsidiaries, in good faith, may not have been charging VAT on certain items to its charity clients appropriately. The Group intends to robustly defend its historical position on this issue which it believes has been in line with historical industry practice. Any backdated VAT assessment arising would be substantially contractually recoverable from clients should this be appropriate. The Group's current estimate of the maximum potential liability before recovery is between £1m and £2m and a non-headline exceptional charge would be made in the event of a claim. The Group will update on this matter as appropriate.

Outlook

The Group begins the new year with good bookings momentum from the last quarter of 2014 and, at this early stage of the year, the Board is confident of a strong trading year ahead.

Preliminary results

The preliminary results for year ended 31 December 2014 will be announced on 19 March 2015.

 

Enquiries:

Cello Group plc (www.cellogroup.com)

 

Mark Scott, Chief Executive

020 7812 8460

Mark Bentley, Group Finance Director

 

 

 

Cenkos Securities

 

Bobbie Hilliam

020 7484 4040

 

 

Buchanan

 

Mark Edwards, Sophie McNulty, Robbie Ceiriog-Hughes

020 7466 5000

www.buchanan.uk.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPKDDPABKDKDB
Date   Source Headline
5th Jun 20181:24 pmRNSBlock listing Interim Review
29th May 20183:45 pmRNSDirector/PDMR Dealings and Total Voting Rights
9th May 20181:14 pmRNSResult of AGM
9th May 20187:00 amRNSAGM Statement
30th Apr 20182:58 pmRNSTotal Voting Rights
26th Apr 20189:45 amRNSChange of Name
25th Apr 20184:45 pmRNSChange of Name update
23rd Apr 201810:28 amRNSChange of name to Cello Health Group plc
16th Apr 20189:30 amRNSAnnual Report and Notice of AGM
22nd Mar 20187:00 amRNSFinal Results
27th Feb 20183:38 pmRNSTotal Voting Rights
18th Jan 20187:00 amRNSPre Close Trading Statement
23rd Nov 20173:54 pmRNSHolding(s) in Company
31st Oct 201711:16 amRNSTotal Voting Rights
26th Oct 20172:37 pmRNSDirector/PDMR Shareholding
29th Sep 20173:43 pmRNSGrant of Options
27th Sep 20174:59 pmRNSDirector/PDMR Shareholding
22nd Sep 201712:05 pmRNSDirector/PDMR Shareholding
20th Sep 20173:58 pmRNSHolding(s) in Company
20th Sep 201711:52 amRNSAdditional Block Listing of Ordinary Shares
20th Sep 20177:00 amRNSInterim Results
31st Aug 20173:19 pmRNSTotal Voting Rights
31st Jul 20173:06 pmRNSTotal Voting Rights
19th Jul 20177:00 amRNSPre Close Trading Statement
18th Jul 20177:00 amRNSAcquisition of Advantage Healthcare Inc
30th Jun 201712:31 pmRNSTotal Voting Rights
23rd Jun 201712:23 pmRNSHolding(s) in Company
14th Jun 201711:33 amRNSDirector/PDMR Shareholding
31st May 201710:27 amRNSTotal Voting Rights
18th May 20172:13 pmRNSHolding(s) in Company
10th May 20175:18 pmRNSHolding(s) in Company
9th May 20172:55 pmRNSResult of AGM
9th May 20177:00 amRNSAGM Statement
2nd May 20173:15 pmRNSIssue of Equity
13th Apr 20172:40 pmRNSAnnual Report and notice of Annual General Meeting
4th Apr 20175:44 pmRNSBlock listing Interim Review
31st Mar 201710:43 amRNSTotal Voting Rights
28th Mar 20173:03 pmRNSHolding(s) in Company
22nd Mar 20177:00 amRNSPreliminary Results
21st Feb 20171:30 pmRNSHolding(s) in Company
20th Feb 20173:19 pmRNSHolding(s) in Company
20th Feb 20179:29 amRNSTotal Voting Rights
17th Feb 201710:40 amRNSResult of General Meeting
1st Feb 20177:00 amRNSPlacing & Acquisition of Defined Health
19th Jan 20177:00 amRNSPre close trading statement
31st Oct 20163:58 pmRNSTotal Voting Rights
28th Oct 201611:37 amRNSDirector/PDMR Shareholding
12th Oct 20167:00 amRNSDirectorate Change
5th Oct 20164:32 pmRNSDirector/PDMR Shareholding
23rd Sep 20165:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.